Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Gilead Sciences, Inc. for the reporting period ending March 31, 2026. The document discloses the company's equity holdings in various issuers as required by the Securities and Exchange Commission.
Key Financial Metrics and Holdings
The filing details specific equity positions held by Gilead Sciences. The table below summarizes the reported holdings:
| Issuer Name | Title of Class | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|---|
| Arcellx Inc | COM | 6,720,803 | $771,682,600 | Sole |
| Arcus Biosciences Inc | COM | 31,424,760 | $678,774,816 | Sole |
| Assembly Biosciences Inc | COM | 4,505,391 | $125,024,600 | Sole |
| Galapagos NV | SPON ADR | 16,707,477 | $501,224,310 | Discretionary |
| Kyverna Therapeutics Inc | COM | 4,126,119 | $35,608,407 | Sole |
| Xilio Therapeutics Inc | COM | 650,389 | $5,469,771 | Sole |
Note: This filing does not provide Gilead Sciences' own revenue, profit, cash flow, margins, debt, or liquidity metrics. It only reports the value of its external equity investments.
Material Changes
The filing text does not provide comparative data for the prior period; therefore, material changes in holdings versus the previous quarter cannot be determined from this document alone.
Guidance, Outlook, and Risks
This Form 13F is a regulatory disclosure of holdings and does not contain management commentary, financial guidance, outlook, or specific risk factors regarding Gilead Sciences' operations. The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness.
Investor Verification Checklist
- Verify the total aggregate value of the disclosed equity positions against Gilead's broader investment portfolio.
- Confirm the voting authority status (Sole vs. Discretionary) for each holding to understand control levels.
- Check subsequent filings to determine if these positions were maintained, increased, or liquidated in the following quarter.
- Review the specific CUSIP numbers to ensure the correct class of securities is identified.